Summit Trail Advisors’s Intersect ENT, Inc XENT Stock Holding History

Summit Trail Advisors’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8	Closed	–	–	1851
2017 Q4	$0	Buy	+8	New	+$240	﹤0.01%	2134

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Trail Advisors's XENT Position: Q1 2018 in Review

Summit Trail Advisors sold out of Intersect ENT, Inc (XENT) in Q1 2018, closing a stake of 8 shares.

Summit Trail Advisors first reported a position in XENT in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 172 funds tracked by Wall St. Rank hold XENT as of Q1 2018.

Summit Trail Advisors reported no remaining Intersect ENT, Inc position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 8 Intersect ENT, Inc shares in Q1 2018.
Summit Trail Advisors first reported a position in Intersect ENT, Inc in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Intersect ENT, Inc position peaked at $0 in Q4 2017.
172 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.